Overview

De-Escalation Therapy for Human Papillomavirus Negative Disease

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the subject's cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Fluorouracil
Hydroxyurea
Lenograstim
Nivolumab
Paclitaxel